Multiple Myeloma | Oncology Today with Dr Neil Love: Key Presentations on the Treatment of Multiple Myeloma from the 2020 ASH Annual Meeting

published 1 month ago by Dr Neil Love

Featuring an interview with Dr Sagar Lonial on the following topics: Early versus late autologous stem cell transplant for newly diagnosed multiple myeloma (NDMM): Long-term follow-up analysis of the IFM 2009 trial Updated analysis of the GRIFFIN trial: Daratumumab with lenalidomide, bortezomib and dexamethasone for transplant-eligible patients with NDMM Phase III TOURMALINE-MM2 trial of oral ixazomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone for transplant-ineligible patients with NDMM Phase III APOLLO study evaluating the addition of subcutaneous daratumumab to pomalidomide and dexamethasone for patients with relapsed/refractory (R/R) MM Selinexor in combination with pomalidomide and dexamethasone for R/R MM Interim analysis of the IKEMA trial evaluating depth of response and response kinetics with isatuximab/carfilzomib/dexamethasone for R/R MM DREAMM-2: Single-agent belantamab mafodotin for patients with R/R MM; 1-year outcomes by prior therapy DREAMM-6: Safety, tolerability and clinical activity of belantamab mafodotin in combination with bortezomib/dexamethasone for R/R MM Updated results from the Phase I CRB-401 study investigating the B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel for R/R MM CARTITUDE-1: A Phase IB/II study of the BCMA–directed CAR T-cell therapy ciltacabtagene autoleucel for R/R MM Updated results from the Phase I CRB-402 study of the anti-BCMA CAR T-cell therapy bb21217 for R/R MM Iberdomide in combination with dexamethasone and either daratumumab or bortezomib for patients with R/R MM Updated results from the Phase I trial of teclistamab, a BCMA x CD3 bispecific antibody for R/R MM Activity and safety of the bispecific antibodies talquetamab and BFCR4350A in patients with R/R MM ANCHOR trial: Updated efficacy and safety data with melflufen in combination with dexamethasone and either daratumumab or bortezomib for R/R MM KarMMa: Efficacy and safety of idecabtagene vicleucel in older patients with R/R MM Assessment of minimal residual disease by next-generation sequencing and FDG-PET/CT for patients with R/R MM treated with venetoclax, carfilzomib and dexamethasone CME information and select publications

more episodes from Research To Practice | Oncology Videos